# US 2013/0096118 A1 · Carboline carboxamide compounds useful as kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0096118 A1
- Document ID: US20130096118A1
- Status: Published application
- Kind: A1
- Application number: 13/704,297
- Filed: 2011-06-16
- Published: 2013-04-18
- Earliest claimed: 2010-06-16
- Assignees: Bristol-Myers Squibb Company
- Inventors: Chunjian Liu; James Lin; George V. DeLucca; Batt G. Douglas; Qingjie Liu
- Web page: https://patentgrep.com/patent/US20130096118A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, formula (I) are useful as kinase modulators, including Btk modulation.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A compound according to formula (I):
or an enantiomer, a diastereomer, a stereoisomer thereof, wherein
X is CR3 or N;
Y is CR3 or N;
Z is CD1 or N;
W is CD2 or N;
— is an optional bond; provided when the two optional bonds are absent, Z is CHD1, W is ND2 or Z is ND1, W is CHD2;
wherein said compound of formula (I) is selected from:
A is C3-10 carbocycle substituted with 0-5 B or C6-10 mono- or bicyclic aryl substituted with 0-5 B;
B is R1, halogen, cyano, nitro, —OR1, —C(═O)R1, —C(═O)OR1, —C(═O)NR11R1, —S(═O)2R1, —NR1C(═O)R1, —NR11C(═O)NR11R1, —NR11C(═O)OR1, —N(C(═O)OR1)2, —NR11S(═O)2R1, —N(S(═O)2R1)2, or —NR11R1;
R1 is hydrogen, C1-6 alkyl substituted with 0-3 R1a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R1a, C2-6 alkynyl substituted with 0-3 R1a, C3-10 cycloalkyl substituted with 0-5 R1a, C6-10 aryl substituted with 0-5 R1a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R1a;
R1a is hydrogen, ═O, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, —(CH2)rORb, —(CH2)rSRb, —(CH2)rC(O)Rb, —(CH2)rC(O)ORb, —(CH2)rOC(O)Rb, —(CH2)rNR11R11, —(CH2)rC(O)NR11R11, —(CH2)rNRbC(O)Rc, —(CH2)rNRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, —(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;
D1 and D2 are independently R2, halogen, —(C(R11)2)rR2, —OR2, —C(═O)R2, —C(═O)OR2, —C(═O)NR11R2, —S(═O)2R2, —S(═O)R2, —SR2, —NR11C(═O)R2, —NR11C(═O)NR11R2, —NR11C(═O)OR2, —NR11S(═O)2R2, —NR11R2, —C(═O)NR11OR2, —OC(═O)OR2, —OC(═O)R2, or —CH═N—OH; alternatively D1 and D2 join to form —O—CH2—O—;
D3 is hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy, or CN;
R2 is hydrogen, C1-6 alkyl substituted with 0-3 R2a, C2-6 alkenyl substituted with 0-3 R2a, C2-6 alkynyl substituted with 0-3 R2a, C3-10 cycloalkyl substituted with 0-5 R2a, C6-10 aryl substituted with 0-5 R2a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R2a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R2a;
R2a is hydrogen, ═O, F, Cl, Br, OCF3, CN, NO2, —(CH2)rORb, —(CH2)rSRb, —(CH2)rC(O)Rb, —(CH2)rC(O)ORb, —(CH2)rOC(O)Rb, —(CH2)rNR11R11, —(CH2)rC(O)NR11R11, —(CH2)rNRbC(O)Rc, —(CH2)rNRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, —(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-2 Ra;
R3 is hydrogen or C1-6 alkyl;
R11 is independently hydrogen or C1-4 alkyl substituted with 0-1 Rf, —CH2-phenyl, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p;
alternatively, R11 along with another R11, R1, or R2 on the same nitrogen atom may join to form an optionally substituted azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or 4-(C1-6 alkyl)piperazinyl;
Ra is hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, —(CH2)rORb, —(CH2)rSRb, —(CH2)rC(O)Rb, —(CH2)rC(O)ORb, —(CH2)rOC(O)Rb, —(CH2)rNR11R11, —(CH2)rC(O)NR11R11, —(CH2)rNRbC(O)Rc, —(CH2)rNRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-1 Rf, C1-6 haloalkyl, —(CH2)r-3-14 membered carbocycle, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p, alternatively two Ra on adjacent or the same carbon atom form a cyclic acetal of the formula —O—(CH2)n—O—, or —O—CF2—O—, wherein n is selected from 1 or 2;
Rb is hydrogen, C1-6 alkyl substituted with 0-2 Rd, C1-6 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or —(CH2)r-phenyl substituted with 0-2 Rd;
Rc is C1-6 alkyl substituted with 0-1 Rf, C3-6 cycloalkyl, or —(CH2)r-phenyl substituted with 0-1 Rf;
Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, —ORe, —(CH2)r(O)Rc, —NReRe, —NReC(O)ORc, C1-6 alkyl, or —(CH2)r-phenyl;
Re is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, or —(CH2)r-phenyl;
Rf is hydrogen, halo, NH2, OH, or OCH3;
r is 0, 1, 2, 3, or 4; and
p is 0, 1, or 2.

### Claim 17 (depends on 16)

The compound according to claim 16, having formula (Ia), (Ib), or (Ic):
wherein A is C6-10 mono- or bicyclic aryl substituted with 0-5 B.

### Claim 18 (depends on 16)

The compound according to claim 16, having formula (Id) or (Ie):
wherein A is C6-10 mono- or bicyclic aryl substituted with 0-5 B.

### Claim 19 (depends on 16)

The compound according to claim 16, wherein formula (I) is formula (If) or (Ig):
wherein A is C6-10 mono- or bicyclic aryl substituted with 0-5 B.

### Claim 20 (depends on 16)

The compound according to claim 16, wherein
D1 and D2 are independently R2, —(CH2)rR2, —OR2, —C(═O)R2, —C(═O)OR2, —C(═O)NR11R2, —S(O)2R2, —S(O)R2, —SR2, —NR11C(O)R2, —NR11C(O)NR11R2, —NR11C(═O)OR2, —NR11S(═O)2R2, or —NR11R2;
R2 is hydrogen, C1-6 alkyl substituted with 0-3 R2a, C2-6 alkenyl substituted with 0-3 R2a, C3-10 cycloalkyl substituted with 0-4 R2a, —C6-10 aryl substituted with 0-4 R2a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R2a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R2a;
R2a is hydrogen, ═O, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, ORb, SRb, —C(O)Rb, —C(O)ORb, —OC(O)Rb, —NR11R11, —C(O)NR11R11, —NRbC(O)Rc, —NRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, —(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, wherein the carbocycle is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-2 Ra; and
r is 0, 1, or 2.

### Claim 21 (depends on 16)

The compound according claim 16, or an enantiomer, a diastereomer, a stereoisomer thereof, wherein said compound of formula (I) is selected from:
B1 is hydrogen, halogen, cyano, nitro, —OH, or C1-6 alkyl substituted with 0-3 R1a;
B2 is R1, —C(═O)R1, —C(═O)OR1, —C(═O)NR11R1, —S(═O)2R1, —NR11C(═O)R1, —NR11C(═O)NR11R1, —NR11C(═O)OR1, —N(C(═O)OR1)2, —NR11S(═O)2R1, —N(S(═O)2R1)2, or —NR11R1;
R1 is hydrogen, C1-6 alkyl substituted with 0-3 R1a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R1a, C2-6 alkynyl substituted with 0-3 R1a, C3-10 cycloalkyl substituted with 0-5 R1a, C6-10 aryl substituted with 0-5 R1a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R1a;
R1a is hydrogen, ═O, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, —(CH2)rORb, —(CH2)rSRb, —(CH2)rC(O)Rb, —(CH2)rC(O)ORb, —(CH2)rOC(O)Rb, —(CH2)rNR11R11, —(CH2)rC(O)NR11R11, —(CH2)rNRbC(O)Rc, —(CH2)rNRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, —(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;
D1 and D2 are independently R2, halogen, —C(R11)2)rR2, —(C(R11)2)rOR2, —C(═O)R2, —C(═O)OR2, —C(═O)NR11R2, —S(═O)2R2, —S(═O)R2, —SR2, —NR11C(═O)R2, —NR11C(═O)NR11R2, —NR11C(═O)OR2, —NR11S(═O)2R2, —NR11R2, —C(═O)NR11OR2, —OC(═O)OR2, —OC(═O)R2, or —CH═N—OH; alternatively D1 and D2 join to form —O—CH2—O—;
D3 is hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy, or CN;
R2 is hydrogen, C1-6 alkyl substituted with 0-3 R2a, C2-6 alkenyl substituted with 0-3 R2a, C2-6 alkynyl substituted with 0-3 R2a, C3-10 cycloalkyl substituted with 0-5 R2a, C6-10 aryl substituted with 0-5 R2a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R2a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-5 R2a;
R2a is hydrogen, ═O, F, Cl, Br, OCF3, CN, NO2, —(CH2)rORb, —(CH2)rSRb, —(CH2)rC(O)Rb, —(CH2)rC(O)ORb, —(CH2)rOC(O)Rb, —(CH2)rNR11R11, —(CH2)rC(O)NR11R11, —(CH2)rNRbC(O)Rc, —(CH2)rNRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, —(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-2 Ra;
R11 is independently hydrogen or C1-4 alkyl substituted with 0-1 Rf, —CH2-phenyl, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p;
alternatively, R11 along with another R11, R1, or R2 on the same nitrogen atom may join to form an optionally substituted azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or 4-(C1-6 alkyl)piperazinyl;
R3 is hydrogen or C1-6 alkyl;
Ra is hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, —(CH2)rORb, —(CH2)rSRb, —(CH2)rC(O)Rb, —(CH2)rC(O)ORb, —(CH2)rOC(O)Rb, —(CH2)rNR11R11, —(CH2)rC(O)NR11R11, —(CH2)rNRbC(O)Rc, —(CH2)rNRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-1 Rf, C1-6 haloalkyl, —(CH2)r-3-14 membered carbocycle, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p; alternatively two Ra on adjacent or the same carbon atom form a cyclic acetal of the formula —O—(CH2)n—O—, or —O—CF2—O—, wherein n is selected from 1 or 2;
Rb is hydrogen, C1-6 alkyl substituted with 0-2 Rd, C1-6 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or —(CH2)r-phenyl substituted with 0-2 Rd;
Rc is C1-6 alkyl substituted with 0-1 Rf, C3-6 cycloalkyl, or —(CH2)r-phenyl substituted with 0-1 Rf;
Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, —ORe, —(CH2)rC(O)Rc, —NReRe, —NReC(O)ORc, C1-6 alkyl, or —(CH2)r-phenyl;
Re is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, or —(CH2)r-phenyl;
Rf is hydrogen, halo, NH2, OH, or OCH3;
r is 0, 1, 2, 3, or 4; and
p is 0, 1, or 2.

### Claim 22 (depends on 21)

The compound according to claim 21 having formula (IIa), (IIb), or (IIc):

### Claim 23 (depends on 21)

The compound according to claim 21 having formula (IId) or (IIe):

### Claim 24 (depends on 21)

The compound according to claim 21 having formula (IIf) or (IIg):

### Claim 25 (depends on 21)

The compound according to claim 21 wherein
B1 is C1-4 alkyl or halogen;
B2 is R1, halogen, C1-4 alkyl, —NR11C(═O)R1, —NR11C(═O)OR1, —NR11C(═O)NR11R1, or —NR11R1;
R1 is hydrogen, C1-4 alkyl, indane or phenyl substituted with 0-3 R1a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a, wherein the heterocyclyl or heteroaryl is selected from
R1a is F, Cl, Br, —NR11R11, —ORb, or C1-6 alkyl substituted with 0-1 Ra;
D1 and D2 are independently R2, halogen, —OR2, —C(═O)R2, —C(═O)OR2, —C(═O)NR11R2, —NR11C(═O)R2, —NR11S(═O)2R2, —SR2, —S(═O)R2, —S(═O)2R2, or —NR11R2; alternatively D1 and D2 join to form —O—CH2—O—;
R2 is hydrogen, C1-6 alkyl substituted with 0-3 R2a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R2a, wherein the heterocyclyl is selected from pyrimidinyl, morpholinyl, piperidinyl, pyrrolidinyl, pyridinyl, tetrahydropyranyl, or tetrahydrofuranyl;
R2a is hydrogen, CN, C1-6 alkyl, —N(CH3)2 or —ORb;
R11 is independently hydrogen, C1-4 alkyl, or —CH2-phenyl;
Ra is hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, —ORb, —SRb, —C(O)Rb, —C(O)ORb, —OC(O)Rb, —NR11R11, —C(O)NR11R11, —NRbC(O)Rc, —NRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl substituted with 0-1 Rf, C1-6 haloalkyl, —(CH2)r-3-6 membered carbocycle, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p, wherein the heterocycle is pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, morpholinyl, thiamorpholinyl, triazolyl, indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, benzimidazolyl, benzopyranyl, benzofuryl, benzisothiazolyl, benzisoxazolyl, benzodiazinyl, or benzofurazanyl;
Rb is hydrogen, C1-4 alkyl substituted with 0-2 Rd, C1-4 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or —(CH2)r-phenyl substituted with 0-2 Rd;
Rc is C1-4 alkyl substituted with 0-1 Rf, C3-6 cycloalkyl, or —(CH2)r-phenyl substituted with 0-1 Rf;
Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, —ORe, —C(O)Rc, —NReRe, —NReC(O)ORc, C1-6 alkyl, or —(CH2)r-phenyl;
Re is hydrogen, C1-4alkyl, C3-6 cycloalkyl, or —(CH2)r-phenyl;
Rf is hydrogen, halo, or NH2; and
r is 0 or 1.

### Claim 26 (depends on 25)

The compound according to claim 25, wherein
Ra is hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, —ORb, —SRb, —C(O)Rb, —C(O)ORb, —OC(O)Rb, —NR11R11, —C(O)NR11R11, —NRbC(O)Rc, —NRbC(O)ORc, —NRbC(O)NR11R11, —S(O)pNR11R11, —NRbS(O)pRc, —S(O)Rc, —S(O)2Rc, C1-6 alkyl, C1-6 haloalkyl, —(CH2)r-3-6 membered carbocycle phenyl, or —(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p, wherein the heterocycle is thiazolyl, pyridinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, or pyrrolidin-one,
Rb is hydrogen, C1-4 alkyl substituted with 0-2 Rd, C1-4 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or —(CH2)r-phenyl substituted with 0-2 Rd;
Rc is C1-4 alkyl, C3-6 cycloalkyl, or —(CH2)r-phenyl;
Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, —ORe, —C(O)Rc, —NReRe, —NHC(O)ORc, C1-4 alkyl, or —(CH2)r-phenyl; and
Re is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or —(CH2)r-phenyl.

### Claim 27 (depends on 25)

The compound according to claim 25 wherein
B1 is methyl or fluorine;
B2 is hydrogen, R1b, —NR11C(═O)R1c, —NR11C(═O)NR11R1d, or —NR11R1e;
R1b is
any of which are substituted with 0-3 R1a;
R1c is C1-6 alkyl,
any of which are substituted with 0-2 Ra;
R1d is phenyl substituted with 0-1 R1a;
R1e is quinazolinyl substituted with 0-1 R1a;
R1a is selected from hydrogen, F, Cl, CN, methyl, ethyl, CF3, OH, and O-methyl;
D1 and D2 are independently selected from R2, F, Cl, Br, —OR2, —C(═O)R2, —C(═O)OR2, —C(═O)NR11R2, —S(═O)2R2, —S(═O)R2, —SR2, —NR11C(═O)R2, —NR11S(═O)2R2, and —NR11R2;
R2 is hydrogen, C1-6 alkyl substituted with 0-3 R2a, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyridinyl, imidazolyl, pyrazinyl, or pyrimidinyl, any of which are substituted with 0-3 R2a;
R2a is hydrogen, CN, —ORb, or morpholinyl;
R11 is hydrogen or C1-4 alkyl;
Ra is hydrogen, F, Cl, C1-4 alkyl, —ORb, —NR11R11, imidazolyl, or morpholinyl; and
Rb is hydrogen or C1-6 alkyl.

### Claim 28 (depends on 16)

A pharmaceutical composition comprising one or more compounds according to claim 16 and a pharmaceutically acceptable carrier or diluent.

### Claim 29 (depends on 16)

A method for treating a disease comprising the administration to a subject in need thereof a therapeutically-effective amount of at least one compound according to claim 16, wherein said disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis (MS), or transplant rejection.

### Claim 30 (depends on 16)

A method of inhibiting Bruton's tyrosine kinase (Btk) comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to claim 16, wherein said disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis (MS), or transplant rejection.
